Prescriptions
Why differentiated insight loses power when it becomes portable, and how sellers preserve value after the recommendation is understood
The fast take
Today’s buyers are better informed, move across about ten channels, and expect a seamless experience that makes it easy to compare options. That improves sense‑making and also shortens the half‑life of any single vendor’s “aha.” Once a prescription is easy to explain internally, it becomes easy to shop. Add that sellers get only 17% of total purchase time with all suppliers; most internal debate about your idea happens when you are not in the room, which accelerates the shift from “insight” to “spec.” [sbigrowth.com] [eprints.bo...outh.ac.uk]
Why agreement accelerates commoditization
The moment a buyer says “this makes sense,” the conversation typically flips from sense‑making to optimization. In that phase, organizations rationally focus on price, risk, and vendor optionality—one reason 86% of B2B purchases stall somewhere and 81% of buyers report dissatisfaction even after they buy. Logic is accepted, but the deal is re‑framed for procurement dynamics. The no‑decision trap compounds this: in 2.5 million analyzed conversations, 40–60% of qualified opportunities ended with no decision, largely due to fear of a wrong call, which nudges teams toward “safe, comparable” specs over distinctive approaches. [ecosystems.io] [info.worldcc.com]
What actually causes the slide from insight to “spec”
Commoditization tends to follow a quiet sequence:
The buyer internalizes your logic and rewrites it in internal language.
The idea is circulated to wider stakeholders across a non‑linear journey of validation and consensus.
Procurement seeks “functionally equivalent” alternatives; your recommendation becomes a requirements list. [b2bexperts.org]
Because these steps occur across ~10 channels and mostly without you (17% seller time), the recommendation detaches from its author quickly. [sbigrowth.com], [eprints.bo...outh.ac.uk]
Why strong prescriptions are most vulnerable
Clear, coherent, replicable prescriptions are easier to share, so they are easier to shop. As late‑gate reviewers engage—security, privacy, finance—the focus shifts to governance proofs and TCO comparisons rather than who originated the idea. Notably, 98% of organizations say external privacy certifications influence purchasing, so competing vendors that wave the same certificates will look interchangeable unless you anchor execution to context. [ecosystems.io]
The difference between prescription and capability
A prescription says what to do. A capability shows how to make it work under this buyer’s constraints, politics, and governance. The more your plan is inseparable from sequencing, ownership, and risk controls inside the customer’s environment, the harder it is to detach and bid out as a commodity spec. Non‑linear buying favors this approach: it gives stakeholders something defendable at each loop (validation, consensus) instead of a one‑time “answer” that anyone can implement. [b2bexperts.org]
Signals your idea has crossed the commodity threshold
Pricing requests arrive before planning conversations.
“Please send a deck we can share internally” proliferates across channels.
Feature checklists appear; procurement engages earlier than expected.
These are consistent with the stall and dissatisfaction pattern: the decision frame has shifted from originality to comparability. [ecosystems.io]
How to prevent premature commoditization
1) Embed the prescription in the buyer’s context.
Package a micro governance pack—recognized privacy certifications and a finance‑ready TCO sensitivity—so risk owners see that your way reduces their workload, not just meets a generic spec. This moves evaluation from “can anyone do this?” to “who can get our gatekeepers to yes?” [ecosystems.io]
2) Sequence and stage custody.
Propose Day‑30/60/90 outcomes with rollback criteria and named owners. This reduces the fear that drives no decision, and it ties your involvement to survivability rather than slides. [info.worldcc.com]
3) Engineer rep‑assisted checkpoints at real gates.
Deals are 1.8× more likely to be rated high‑quality when supplier tools are paired with a rep at critical decision points. Orchestrate those sessions around security sign‑off, CFO reviews, and phase exits to keep capability, not just concept, in focus. [gartner.com]
4) Avoid full specificity before ownership is real.
In non‑linear journeys, final blueprints delivered too early become portable specs. Withhold final detail until the internal owner and metrics are confirmed, then bind specificity to that role’s calendar and risks. [b2bexperts.org]
If commoditization has already started, re‑anchor value
Shift the narrative from idea superiority to risk reduction and orchestration. Emphasize execution complexity, cross‑functional alignment, and the cost of post‑signature rework—on average ~8.6% value erosion when expectations and scope aren’t aligned up front. Position your team as the safest path through those landmines, not just the originator of the plan. [link.springer.com]
Mini‑playbook
Anchor to governance: Lead with privacy certifications + TCO sensitivity. [ecosystems.io]
Stage commitment: Day‑30/60/90 metrics, explicit rollback, named owner. [info.worldcc.com]
Control the gates: Rep‑assisted reviews where decisions actually happen; capture the 1.8× quality lift. [gartner.com]
Watch for frame shift: Early procurement involvement or checklist requests mean the idea is now a spec; pivot to capability and risk. [ecosystems.io]
The punchline
Prescriptions turn into commodities the moment they can live without you. In omnichannel, consensus‑heavy buying, insight is table stakes; execution under real constraints is the scarce resource. Design your recommendations so they are inseparable from sequencing, governance, and role‑based custody—and when comparison shopping begins, compete on survivability, not originality. [sbigrowth.com], [b2bexperts.org], [ecosystems.io]
